Nanjing Vazyme Biotech Co., Ltd (SHA:688105)

Market Cap	8.26B -1.6%
Revenue (ttm)	1.34B -4.2%
Net Income	-29.64M
EPS	-0.09
Shares Out	397.73M
PE Ratio	n/a
Forward PE	155.85
Dividend	0.30 (1.44%)
Ex-Dividend Date	n/a

Volume	794,434
Average Volume	1,830,039
Open	20.89
Previous Close	20.90
Day's Range	20.76 - 21.10
52-Week Range	19.58 - 26.77
Beta	0.89
RSI	43.07
Earnings Date	Apr 23, 2026

About Nanjing Vazyme Biotech

Nanjing Vazyme Biotech Co., Ltd offers technology solutions for life science, biomedicine, and in vitro diagnostics. The company offers nucleic acid extraction reagents, including DNA extraction, RNA extraction, microbiome nucleic acid extraction, sample treatment, and high-throughput automated extraction; molecular biology reagents comprising PCR, cloning/mutagenesis, reverse transcription, real-time PCR (qPCR), one-step RT-PCR/RT-qPCR, nucleic acid electrophoresis, genome editing techniques, isothermal amplification, and instant granules; and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 2,754
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688105

Financial Performance

In 2024, Nanjing Vazyme Biotech's revenue was 1.38 billion, an increase of 7.15% compared to the previous year's 1.29 billion. Losses were -18.09 million, -74.50% less than in 2023.